Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical trials.

PARIS (Reuters) -French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

Sanofi's expertise in the selection of therapeutic targets is complementary to the know-how and technology platforms developed at the Institut Curie." Damien Salauze, director of Curie-Cancer.

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their blockbuster Dupixent in the I&I space, was “contrary to our expectations—we were ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Sanofi plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research, joining other drugmakers in expanding their U.S. presence in response to President ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.